Skip to main content
Top
Published in: Neurological Sciences 1/2013

01-05-2013 | ANIRCEF - HCNE JOINT MEETING

Disability and quality of life in headache: where we are now and where we are heading

Authors: D. D’Amico, L. Grazzi, S. Usai, M. Leonardi, A. Raggi

Published in: Neurological Sciences | Special Issue 1/2013

Login to get access

Abstract

Headache disorders determine relevant personal and societal burden, and thus the use of patient-reported outcome measures (PROMs) investigating the level of disability and health-related quality of life (HRQoL) have been increasingly used in headache research. The aim of this review was to address the status of research on disability and HRQoL, by addressing results from recently published clinical trials as well as in longitudinal observational studies on headache patients. PubMed has been searched for papers in which measures of HRQoL and/or disability were used as primary or secondary outcome on adult subjects with primary headache, and published in 2010–2012. Among the 70 records retrieved, 12 papers were selected for narrative synthesis. They included data on 2,621 patients with episodic migraine with and without aura, chronic daily headache, and/or chronic migraine with and without medication overuse. The selected trials investigated the efficacy of different pharmacological prophylaxis, of some surgical approaches, of education programmes and osteopathic manipulative treatment; two studies reported longitudinal observations of patients currently under treatment. Overall, the results of our review showed that headache frequency as well as HRQoL and disability were positively impacted by treatment interventions; positive outcomes were less evident in two studies, and similar results were found in the two observational studies. Our findings confirmed that the most commonly used PROMs, including disease-specific tools to assess disability and HRQoL and SF-36, are sensitive to the beneficial effects occurring over time in functioning and quality of life domains in headache patients. They also suggest that the personal and societal costs of headache disorders are likely to be reduced when headache patients receive appropriate treatments and when continuity of care is offered. In terms of future directions, we note that the systematic use of appropriate PROMs should be encouraged both in the clinical practice and in the research field, as they offer a valid option to assess the global effect of treatments on patient-perceived sense of well-being and quality of performance.
Literature
1.
go back to reference Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422–435PubMed Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422–435PubMed
2.
go back to reference Raggi A, Giovannetti AM, Quintas R, D’Amico D, Cieza A, Sabariego C, Bickenbach JE, Leonardi M (2012) A systematic review of the psychosocial difficulties relevant to patients with migraine. J Headache Pain 13:595–606PubMedCrossRef Raggi A, Giovannetti AM, Quintas R, D’Amico D, Cieza A, Sabariego C, Bickenbach JE, Leonardi M (2012) A systematic review of the psychosocial difficulties relevant to patients with migraine. J Headache Pain 13:595–606PubMedCrossRef
3.
go back to reference D’Amico D, Grazzi L, Usai S, Raggi A, Leonardi M, Bussone G (2011) Disability in chronic daily headache: state of the art and future directions. Neurol Sci 32:S71–S76PubMedCrossRef D’Amico D, Grazzi L, Usai S, Raggi A, Leonardi M, Bussone G (2011) Disability in chronic daily headache: state of the art and future directions. Neurol Sci 32:S71–S76PubMedCrossRef
4.
go back to reference Lantéri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability, and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837–850PubMedCrossRef Lantéri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability, and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837–850PubMedCrossRef
5.
go back to reference Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936CrossRef Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936CrossRef
6.
go back to reference Beran RG, Spira PJ (2011) Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia 31:530–536PubMedCrossRef Beran RG, Spira PJ (2011) Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia 31:530–536PubMedCrossRef
7.
go back to reference Holroyd KA, Cottrell CK, O’Donnell FJ, Cordingley GE, Drew JB, Carlson BW, Himawan L (2010) Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 341:c4871PubMedCrossRef Holroyd KA, Cottrell CK, O’Donnell FJ, Cordingley GE, Drew JB, Carlson BW, Himawan L (2010) Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 341:c4871PubMedCrossRef
8.
go back to reference Seng EK, Holroyd KA (2012) Psychiatric comorbidity and response to preventative therapy in the treatment of severe migraine trial. Cephalalgia 32:390–400PubMedCrossRef Seng EK, Holroyd KA (2012) Psychiatric comorbidity and response to preventative therapy in the treatment of severe migraine trial. Cephalalgia 32:390–400PubMedCrossRef
9.
go back to reference Guyuron B, Kriegler JS, Davis J, Amini SB (2011) Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg 127:603–608PubMedCrossRef Guyuron B, Kriegler JS, Davis J, Amini SB (2011) Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg 127:603–608PubMedCrossRef
10.
go back to reference Faber C, Garcia RM, Davis J, Guyuron B (2012) A socioeconomic analysis of surgical treatment of migraine headaches. Plast Reconstr Surg 129:871–877PubMedCrossRef Faber C, Garcia RM, Davis J, Guyuron B (2012) A socioeconomic analysis of surgical treatment of migraine headaches. Plast Reconstr Surg 129:871–877PubMedCrossRef
11.
go back to reference Serra G, Marchioretto F (2012) Occipital nerve stimulation for chronic migraine: a randomized trial. Pain Physician 15:245–253PubMed Serra G, Marchioretto F (2012) Occipital nerve stimulation for chronic migraine: a randomized trial. Pain Physician 15:245–253PubMed
12.
go back to reference Novack V, Fuchs L, Lantsberg L, Kama S, Lahoud U, Horev A, Loewenthal N, Ifergane G (2011) Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series. Cephalalgia 31:1336–1342PubMedCrossRef Novack V, Fuchs L, Lantsberg L, Kama S, Lahoud U, Horev A, Loewenthal N, Ifergane G (2011) Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series. Cephalalgia 31:1336–1342PubMedCrossRef
13.
go back to reference Raggi A, Leonardi M, Bussone G, D’Amico D (2011) Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life. Neurol Sci 32(3):387–392PubMedCrossRef Raggi A, Leonardi M, Bussone G, D’Amico D (2011) Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life. Neurol Sci 32(3):387–392PubMedCrossRef
14.
go back to reference Raggi A, Leonardi M, Bussone G, D’Amico D (2013) A 3-month analysis of disability, quality of life, and disease course in patients with migraine. Headache 53:297–309PubMedCrossRef Raggi A, Leonardi M, Bussone G, D’Amico D (2013) A 3-month analysis of disability, quality of life, and disease course in patients with migraine. Headache 53:297–309PubMedCrossRef
15.
go back to reference Smith TR, Nicholson RA, Banks JW (2010) Migraine education improves quality of life in a primary care setting. Headache 50:600–612PubMedCrossRef Smith TR, Nicholson RA, Banks JW (2010) Migraine education improves quality of life in a primary care setting. Headache 50:600–612PubMedCrossRef
16.
go back to reference Voigt K, Liebnitzky J, Burmeister U, Sihvonen-Riemenschneider H, Beck M, Voigt R, Bergmann A (2011) Efficacy of osteopathic manipulative treatment of female patients with migraine: results of a randomized controlled trial. J Altern Complement Med 17:225–230PubMedCrossRef Voigt K, Liebnitzky J, Burmeister U, Sihvonen-Riemenschneider H, Beck M, Voigt R, Bergmann A (2011) Efficacy of osteopathic manipulative treatment of female patients with migraine: results of a randomized controlled trial. J Altern Complement Med 17:225–230PubMedCrossRef
17.
go back to reference Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41–52PubMedCrossRef Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41–52PubMedCrossRef
18.
go back to reference Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974PubMedCrossRef Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974PubMedCrossRef
19.
go back to reference Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache 38:295–302PubMedCrossRef Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache 38:295–302PubMedCrossRef
21.
go back to reference Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME (2010) Adherence to acute migraine medication: what does it mean, why does it matter? Headache 50:117–129PubMedCrossRef Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME (2010) Adherence to acute migraine medication: what does it mean, why does it matter? Headache 50:117–129PubMedCrossRef
22.
go back to reference D’Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4:1155–1167PubMedCrossRef D’Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4:1155–1167PubMedCrossRef
23.
go back to reference Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T; International Headache Society Clinical Trials Subcommittee (2012) Guidelines for controlled trials of drugs in migraine: 3rd edn. A guide for investigators. Cephalalgia 32(1):6–38CrossRef Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D’Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T; International Headache Society Clinical Trials Subcommittee (2012) Guidelines for controlled trials of drugs in migraine: 3rd edn. A guide for investigators. Cephalalgia 32(1):6–38CrossRef
24.
go back to reference Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ; Task Force of the International Headache Society Clinical Trials Subcommittee (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28(5):484–495CrossRef Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ; Task Force of the International Headache Society Clinical Trials Subcommittee (2008) Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 28(5):484–495CrossRef
Metadata
Title
Disability and quality of life in headache: where we are now and where we are heading
Authors
D. D’Amico
L. Grazzi
S. Usai
M. Leonardi
A. Raggi
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2013
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-013-1378-9

Other articles of this Special Issue 1/2013

Neurological Sciences 1/2013 Go to the issue

PATHOPHYSIOLOGY OF MIGRAINE

Nociception and autonomic nervous system

TRIGEMINO AUTONOMICS CEPHALALGIAS (TACs)

SUNCT and SUNA: medical and surgical treatments